P933: INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.

Detalles Bibliográficos
Autores principales: Mol, Isha, Hu, Yannan, Cappelleri, Joseph, Chu, Haitao, Aydin, Didem, Hlavacek, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431132/
http://dx.doi.org/10.1097/01.HS9.0000970636.73112.6c
_version_ 1785091128150720512
author Mol, Isha
Hu, Yannan
Cappelleri, Joseph
Chu, Haitao
Aydin, Didem
Hlavacek, Patrick
author_facet Mol, Isha
Hu, Yannan
Cappelleri, Joseph
Chu, Haitao
Aydin, Didem
Hlavacek, Patrick
author_sort Mol, Isha
collection PubMed
description
format Online
Article
Text
id pubmed-10431132
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104311322023-08-17 P933: INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA. Mol, Isha Hu, Yannan Cappelleri, Joseph Chu, Haitao Aydin, Didem Hlavacek, Patrick Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431132/ http://dx.doi.org/10.1097/01.HS9.0000970636.73112.6c Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Mol, Isha
Hu, Yannan
Cappelleri, Joseph
Chu, Haitao
Aydin, Didem
Hlavacek, Patrick
P933: INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
title P933: INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
title_full P933: INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
title_fullStr P933: INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
title_full_unstemmed P933: INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
title_short P933: INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
title_sort p933: indirect treatment comparison of elranatamab with belmaf, sel-dex, and real-world physician’s choice of treatment in patients with triple-class exposed relapsed/refractory multiple myeloma.
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431132/
http://dx.doi.org/10.1097/01.HS9.0000970636.73112.6c
work_keys_str_mv AT molisha p933indirecttreatmentcomparisonofelranatamabwithbelmafseldexandrealworldphysicianschoiceoftreatmentinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma
AT huyannan p933indirecttreatmentcomparisonofelranatamabwithbelmafseldexandrealworldphysicianschoiceoftreatmentinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma
AT cappellerijoseph p933indirecttreatmentcomparisonofelranatamabwithbelmafseldexandrealworldphysicianschoiceoftreatmentinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma
AT chuhaitao p933indirecttreatmentcomparisonofelranatamabwithbelmafseldexandrealworldphysicianschoiceoftreatmentinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma
AT aydindidem p933indirecttreatmentcomparisonofelranatamabwithbelmafseldexandrealworldphysicianschoiceoftreatmentinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma
AT hlavacekpatrick p933indirecttreatmentcomparisonofelranatamabwithbelmafseldexandrealworldphysicianschoiceoftreatmentinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma

Ejemplares similares